Class / Patent application number | Description | Number of patent applications / Date published |
424569000 | Cardiovascular system, other than umbilical artery or vein (e.g., blood vessel, heart, cardiac muscle, etc.) | 15 |
20080305181 | Compositions and Methods for Treatment of Vascular Grafts - The present invention contemplates compositions and methods for the treatment of vascular grafts both ex vivo and in vivo. Ex vivo treatment comprises completely removing a vessel (i.e., vein or artery) from the body and treating with the compositions of the present invention. In vivo treatment comprises treating the vessel in vivo without removing the vessel completely from the body (albeit one or both ends of the vessel may be closed off in order to focus the treatment in the desired area and/or avoid systemic treatment). In one embodiment, at least a portion of the smooth muscle cells of a vessel (e.g., vein or artery) are transfected ex vivo or in vivo with a vector capable of expressing at least one phosphatase. In a preferred embodiment, smooth muscle cells are transfected with adenovirus vector comprising the gene encoding PTEN. | 12-11-2008 |
20090028959 | PHARMACEUTICAL COMPOSITION AND METHOD FOR REGENERATING MYOFIBERS IN THE TREATMENT OF MUSCLE INJURIES - A pharmaceutical composition and method for regenerating cardiomyocytes in treating or repairing heart muscle damages or injuries caused by an ischemic disease. The pharmaceutical composition contains an active ingredient compound with a backbone structure of Formula (I). The active ingredient compound is capable of (a) increasing viability of myogenic precursor cells to enable said precursor cells to survive through an absolute ischemic period; (b) reconstituting a damaged blood supply network in said heart region where said injured muscle is located; and (c) enhancing cardiomyogenic differentiation efficiency of said precursor cells down cardiac linage, said steps being performed simultaneously or in any particular order. | 01-29-2009 |
20130156862 | Extracellular Matrix-Derived Gels and Related Methods - Provided are methods for preparing gelled, solubilized extracellular matrix (ECM) compositions useful as cell growth scaffolds. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which the gelled, solubilized ECM is dispersed to facilitate in-growth of cells into the ECM and thus adaptation and/or attachment of the device to a patient. | 06-20-2013 |
20140087000 | Method and System for Treatment of Biological Tissue - A composition for reconstruction, replacement or repair of damaged or diseased biological tissue comprising an extracellular matrix (ECM) composition that includes an ECM scaffold component derived from a mammalian source and at least one additional bioactive component selected from the group consisting of a statin and a chitin derivative. | 03-27-2014 |
20140186460 | Elastic Tissue Matrix Derived Hydrogel - A tissue-derived hydrogel, as well as methods of making and using such hydrogels, are provided. | 07-03-2014 |
20140234434 | Tissue for Prosthetic Implants and Grafts, and Methods Associated Therewith - A prepared tissue for medical use with a patient is provided. Methods for preparing such tissue are also provided. Implantable tissue is provided by harvesting a tissue, such as but not limited to a pericardium tissue, and exposing the tissue to various cleaning, rinsing, treatment, separating, and fixation steps. The tissue of at least one embodiment is cleaned with distilled water, rinsed with isopropyl alcohol, and treated with a glutaraldehyde solution. The prepared tissue may be allowed to dry or partially hydrated prior to packaging and shipment. As such, the tissue can be implanted into the receiving patient in either a dry or wet state. The relatively thin yet strong tissue material is adapted for implanting within or grafting to human tissue. By way of example, the tissue may be used in a shunt, a valve, as graft material, as a patch, as a prosthetic tissue in a tendon and/or ligament, and a tissue product for wound management. | 08-21-2014 |
20150037433 | METHOD FOR PREPARING BIOLOGICAL TISSUE - A method for preparing tissue for medical applications, in particular tissue for use for an artificial heart valve, wherein the method has the steps of decellularizing the tissue by means of a detergent and subsequently cross-linking the collagen fibers of the tissue by means of a suitable cross-linking agent. At least one lipopeptide, such as surfactin, for example, is used as the detergent for decellularization. | 02-05-2015 |
20160000834 | METHODS AND COMPOSITIONS FOR TISSUE THERAPY AND ANALYSIS - Methods and compositions comprising a biomaterial that are useful for treating a subject with a condition are described. More specifically, methods of treating a subject with a cardiovascular condition comprising delivering a biomaterial comprising extracellular matrix, and delivering a therapeutic cardiac device or therapeutic agents to the subject are described. In addition, methods of delivering extracellular matrix to a subject are also described. | 01-07-2016 |
20160022865 | Aligned Fiber and Method of Use Thereof - A scaffold comprising an aligned fiber. The invention further relates to a scaffold comprising one or more electrospun fibers wherein a fast Fourier transform (FFT) analysis result of the fibers have adjacent major peaks with about 180? apart from each other. Methods for promoting differentiation of stem cells into osteoblasts, chondrocytes, ligament or tendon, the method comprising culturing the cells on the scaffold or aligned fiber in conditions suitable for the cell differentiation. | 01-28-2016 |
20160067031 | METHODS AND USES OF MEDIASTINAL PLEURA TISSUE FOR VARIOUS STENT AND OTHER MEDICAL APPLICATIONS - Methods, products and uses of or relating to biological tissues for various stent and other medical applications are disclosed. In an exemplary embodiment of a method of processing a tissue of the present disclosure, the method comprises the steps of acquiring a tissue comprising at least a portion of parietal pleura, selecting a sample of mediastinal pleura tissue from the parietal pleura tissue, and fixing the sample of mediastinal pleura tissue using a fixative, resulting in a fixed sample. Furthermore, in an embodiment of a tissue product of the present disclosure, the tissue product comprises a frame configured to retain mediastinal pleura tissue thereon and such tissue coupled to the frame. | 03-10-2016 |
20160067286 | Formulation for Accelerating Wound Healing, Preparation Method and Administering Method of The Same - Disclosed is a formulation for accelerating wound healing, preparation method and administering method of the same. A formulation for accelerating wound healing comprises cell culture medium which is obtained by culturing transfected endothelial progenitor cells which are acquired by transfecting microRNA let-7g into endothelial progenitor cells. And the preparation method of formulation for accelerating wound healing comprises the isolating step, the transfecting step and the culturing step. A method for accelerating wound healing is implemented by administering a therapeutically effective amount of the formulation to an organism's wound. | 03-10-2016 |
20160097099 | BIOMARKERS FOR THE MOLECULAR CLASSIFICATION OF BACTERIAL INFECTION - Disclosed herein are biomarkers useful for identifying and/or classifying bacterial infections in a subject. | 04-07-2016 |
20160139160 | CARDIOVASCULAR DISEASE RISK ASSESSMENT - The invention provides improved methods for analyzing cardiovascular disease risk. According to the invention, an algorithm that considers LDL and HDL subfractions, along with Lp(a) provides significant improvement in predicting CVD versus standard assays that include standard risk factors. Methods of the invention comprise measuring LDL and HDL subfractions in addition to Lp(a) without reference to standard risk factor measurements, such as CRP, total cholesterol, body mass index, weight, triglycerides, and the like. It is unexpected that an algorithm focusing only on LDL and HDL subfractions and Lp(a) would be more informative as to CVD risk than measurements that are much more comprehensive in terms of the markers that are reviewed. In particular, the sdLDL-C subfraction of LDL and the ApoA-1 in large alpha-1 HDL are most informative in conjunction with Lp(a). | 05-19-2016 |
20160158291 | PROCESSES FOR PRODUCING STABLE EXOSOME FORMULATIONS - The invention encompasses methods for generating stable exosome formulations and encompasses stable exosome formulations. The exosome formulations encompass stable liquid exosome formulations and stable lyophilized exosome formulations. In some embodiments, the exosome formulations can be generated by ultrafiltration and diafiltration. The exosome formulations can be suitable for administration to a human. | 06-09-2016 |
20180021478 | DETOXIFICATION AND STABILIZATION OF IMPLANTABLE OR TRANSPLANTABLE BIOLOGICAL MATERIAL | 01-25-2018 |